Kerstjens HA - Search Results

1

Impact on clinical decision making of quality control standards applied to sputum analysis in COPD.

Telgen MC, Brusse-Keizer MG, van der Valk PD, van der Palen J, Kerstjens HA, Hendrix MG. Telgen MC, et al. Among authors: kerstjens ha. Respir Med. 2011 Mar;105(3):371-6. doi: 10.1016/j.rmed.2010.10.009. Epub 2010 Nov 18. Respir Med. 2011. PMID: 21093241 Free article.

2

Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD.

Liesker JJ, Van De Velde V, Meysman M, Vincken W, Wollmer P, Hansson L, Kerstjens HA, Qvint U, Pauwels RA. Liesker JJ, et al. Among authors: kerstjens ha. Respir Med. 2002 Aug;96(8):559-66. doi: 10.1053/rmed.2001.1335. Respir Med. 2002. PMID: 12195835 Free article. Clinical Trial.

3

Cognitive performance in patients with COPD.

Liesker JJ, Postma DS, Beukema RJ, ten Hacken NH, van der Molen T, Riemersma RA, van Zomeren EH, Kerstjens HA. Liesker JJ, et al. Among authors: kerstjens ha. Respir Med. 2004 Apr;98(4):351-6. doi: 10.1016/j.rmed.2003.11.004. Respir Med. 2004. PMID: 15072176 Free article.

4

Health-related quality of life in COPD patients with chronic respiratory failure.

Duiverman ML, Wempe JB, Bladder G, Kerstjens HA, Wijkstra PJ. Duiverman ML, et al. Among authors: kerstjens ha. Eur Respir J. 2008 Aug;32(2):379-86. doi: 10.1183/09031936.00163607. Epub 2008 Apr 2. Eur Respir J. 2008. PMID: 18385168 Free article.

5

Relation of sputum colour to bacterial load in acute exacerbations of COPD.

Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, Telgen MC, van der Palen J, Hendrix MG, van der Valk PD. Brusse-Keizer MG, et al. Among authors: kerstjens ha. Respir Med. 2009 Apr;103(4):601-6. doi: 10.1016/j.rmed.2008.10.012. Epub 2008 Nov 22. Respir Med. 2009. PMID: 19027281 Free article.

6

Copd.

Kerstjens HA, Postma DS, Ten Hacken N. Kerstjens HA, et al. BMJ Clin Evid. 2008 Dec 15;2008:1502. BMJ Clin Evid. 2008. PMID: 19445783 Free PMC article. Review.

7

(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study.

Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J. Effing T, et al. Thorax. 2009 Nov;64(11):956-62. doi: 10.1136/thx.2008.112243. Epub 2009 Sep 6. Thorax. 2009. PMID: 19736179 Clinical Trial.

8

Definitions of exacerbations: does it really matter in clinical trials on COPD?

Effing TW, Kerstjens HAM, Monninkhof EM, van der Valk PDLPM, Wouters EFM, Postma DS, Zielhuis GA, van der Palen J. Effing TW, et al. Chest. 2009 Sep;136(3):918-923. doi: 10.1378/chest.08-1680. Chest. 2009. PMID: 19736196 Review.

9

Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.

Kerstjens HA, Bjermer L, Eriksson L, Dahlström K, Vestbo J. Kerstjens HA, et al. Respir Med. 2010 Sep;104(9):1297-303. doi: 10.1016/j.rmed.2010.04.010. Epub 2010 May 13. Respir Med. 2010. PMID: 20466530 Free article. Clinical Trial.

10

Multidrug resistance-associated protein-1 (MRP1) genetic variants, MRP1 protein levels and severity of COPD.

Budulac SE, Postma DS, Hiemstra PS, Kunz LI, Siedlinski M, Smit HA, Vonk JM, Rutgers B, Timens W, Boezen HM; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study group. Budulac SE, et al. Respir Res. 2010 May 20;11(1):60. doi: 10.1186/1465-9921-11-60. Respir Res. 2010. PMID: 20487524 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

387 results

Search Page

Filters